Retevmo safety and tolerability were evaluated in 702 patients1
- Dose interruptions and dose reductions due to ARs occurred in 42% and 31% of patients who received Retevmo, respectively.1 See full Prescribing Information for dose modifications.
- ARs requiring dosage interruption in ≥2% of patients included ALT increased, AST increased, hypertension, diarrhea, pyrexia, and QT prolongation.1
- ARs requiring dosage reductions in ≥2% of patients included ALT increased, AST increased, QT prolongation, and fatigue.1
5% (n=37) of patients discontinued Retevmo (N=702) due to adverse reactions; 2% (n=14) were considered treatment-related, as assessed by trial investigator. Adverse reactions resulting in permanent discontinuation in patients who received Retevmo included increased ALT (0.4%), sepsis (0.4%), increased AST (0.3%), drug hypersensitivity (0.3%), fatigue (0.3%), and thrombocytopenia (0.3%).1,3
Due to rounding and potential double-counting of patients, percentages presented may not add up to the indicated totals.
*Diarrhea, abdominal pain, fatigue, edema, rash, headache, cough, dyspnea, and hemorrhage are consolidated terms. See full Prescribing Information for list of consolidated terms.
†In the LIBRETTO-001 trial, 1% of patients experienced Grade 1/2 pneumonitis/interstitial lung disease (ILD); no patients experienced Grade 3/4 or fatal pneumonitis/ILD.2
‡Denominator for each laboratory parameter is based on the number of patients with a baseline and post-treatment laboratory value available, which ranged from 675 to 692 patients.1